HS
EWTX icon

HighVista Strategies’s Edgewise Therapeutics EWTX Stock Holding History

HighVista Strategies’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Sell
91,931
-79,206
-46% -$2.28M 0.8% 40
2025
Q4 		$4.25M Sell
171,137
-36,964
-18% -$742K 1.09% 29
2025
Q3 		$3.38M Buy
208,101
+138,378
+198% +$1.96M 0.83% 33
2025
Q2 		$914K Sell
69,723
-21,484
-24% -$310K 0.34% 113
2025
Q1 		$2.01M Buy
91,207
+8,475
+10% +$222K 0.77% 38
2024
Q4 		$2.21M Sell
82,732
-6,106
-7% -$194K 0.82% 37
2024
Q3 		$2.37M Buy
+88,838
New +$1.77M 0.82% 36
2023
Q1 		– Sell
-187,480
Closed -$1.68M – 115
2022
Q4 		$1.68M Buy
187,480
+84,018
+81% +$788K 1% 32
2022
Q3 		$1.02M Hold
103,462
– – 0.58% 41
2022
Q2 		$824K Buy
103,462
+43,729
+73% +$331K 0.5% 43
2022
Q1 		$579K Buy
+59,733
New +$769K 0.37% 67
2021
Q4 		– Sell
-39,133
Closed -$650K – 86
2021
Q3 		$650K Buy
39,133
+11,666
+42% +$211K 0.43% 65
2021
Q2 		$586K Buy
+27,467
New +$751K 0.42% 68

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighVista Strategies's EWTX Position: Q1 2026 in Review

HighVista Strategies reduced its Edgewise Therapeutics (EWTX) stake by 46% in Q1 2026, selling an estimated $2.28M and leaving 91,931 shares worth $2.9M. The position accounts for 0.8% of the portfolio, ranked #40.

HighVista Strategies first reported a position in EWTX in Q2 2021 and has held it in 13 quarters since. The position peaked at $4.25M in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • HighVista Strategies held 91,931 shares of Edgewise Therapeutics worth $2.9M as of Q1 2026.
  • HighVista Strategies sold 79,206 Edgewise Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Edgewise Therapeutics made up 0.8% of HighVista Strategies's portfolio in Q1 2026, its #40 holding.
  • HighVista Strategies first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • HighVista Strategies's Edgewise Therapeutics position peaked at $4.25M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.